PRTCL.
Legal & Regulatory

Is retatrutide legally available yet?

Updated 2026-05-02

No. As of April 2026, retatrutide (LY3437943) is an investigational drug. It is not approved for sale in the US or any other major market. Eli Lilly is running seven Phase 3 trials under the TRIUMPH program. TRIUMPH-4 read out in December 2025 (28.7% mean weight loss at 68 weeks on 12 mg), but the full Phase 3 package for a New Drug Application is still being assembled. Estimated approval: late 2027 to Q1 2028. Anything sold as retatrutide right now is unregulated, unverified, and potentially dangerous.

IfIf a website is selling retatrutide today
Thenthen it is not the validated pharmaceutical compound - it is an unregulated research chemical
IfIf you want to access retatrutide legally
Thenthen search ClinicalTrials.gov for TRIUMPH Phase 3 enrollment sites
IfIf you're told it's approved somewhere
Thenthen verify on that country's regulator website - as of April 2026, no major jurisdiction has approved it
Key facts
  • Current status: investigational; Phase 3 TRIUMPH trials ongoing
  • TRIUMPH-4 readout: December 2025; 28.7% mean weight loss at 68 weeks on 12 mg
  • Phase 2 (Jastreboff et al. 2023): 24.2% weight loss at 48 weeks on 12 mg
  • NDA submission: expected Q4 2026 or Q1 2027
  • Review period: typically 10 to 12 months (Priority Review 6 months possible)
  • Estimated US approval: late 2027 to Q1 2028
Get more like this

Your guided peptide companion.

PRTCL walks beginners through their first peptide with confidence - guided reconstitution, dose calculation, vial tracking, and answers to questions like this one. Built for first-timers, useful for everyone.

  • · Guided walkthrough for your first dose
  • · Dose calculator that does the math for you
  • · Vial inventory and dose log tracking
  • · Library of physician-vetted protocols

Free to start.

PRTCL is educational. Always talk to a licensed provider about your situation.